Rapporto sulle dimensioni del mercato del trattamento della sindrome dell’ovaio policistico (PCOS) e sull’analisi delle quote | Previsioni 2030

  • Report Code : TIPRE00004072
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

Le previsioni di mercato del trattamento della sindrome dell'ovaio policistico (PCOS) aiutano le parti interessate in questo mercato a delineare le loro strategie di crescita. Si prevede che il mercato crescerà da 3,46 miliardi di dollari nel 2023 a 5,26 miliardi di dollari entro il 2031; si stima che registrerà un CAGR del 5,4% nel 2023-2031.< /strong>

L'aumento della prevalenza della PCOS a livello globale, insieme a un aumento significativo della spesa sanitaria per il trattamento della PCOS, sono i fattori che spingono la sindrome dell'ovaio policistico (PCOS) crescita del mercato dei trattamenti. Ad esempio, circa 6 milioni di donne negli Stati Uniti soffrono di PCOS, uno squilibrio ormonale comune. Aumenta il rischio di diverse malattie, come il cancro dell’endometrio, l’ipertensione, il diabete di tipo 2, l’infertilità e l’ictus. Inoltre, la Endocrine Society stima che la diagnosi e il trattamento della sindrome dell'ovaio policistico (PCOS), il disturbo ormonale più diffuso che colpisce le donne in età riproduttiva, costerà 8 miliardi di dollari a livello nazionale nel 2020.

Lo sviluppo di nuove terapie porterà nuovetendenze di mercato per il trattamento della sindrome dell'ovaio policistico (PCOS) durante il periodo di previsione.

< u>Fattori di crescita:

L'aumento della prevalenza della PCOS tra le donne a livello globale guida la crescita del mercato del trattamento della sindrome dell'ovaio policistico (PCOS)

Analisi regionale:

In termini geografici, la portata della sindrome dell'ovaio policistico (PCOS ) Il rapporto sul mercato dei trattamenti include Nord America, Europa, Asia Pacifico, Sud & America Centrale e Medio Oriente e Medio Oriente Africa. Nel 2023, il Nord America deteneva la quota di mercato maggiore. La crescente adozione delle più recenti tecnologie dei dispositivi medici, la crescente prevalenza della PCOS e le crescenti innovazioni di prodotto da parte dei principali attori contribuiscono alla crescita delle dimensioni del mercato del trattamento della sindrome dell'ovaio policistico (PCOS) in Nord America. Secondo il Dipartimento di Salute & Servizi umani, la PCOS è una causa comune di infertilità femminile negli Stati Uniti, che colpisce dal 6% al 12% circa (~ 5 milioni) di donne statunitensi in età riproduttiva. Secondo lo studio "Incidenza, prevalenza e tendenze nella diagnosi della sindrome dell'ovaio policistico", pubblicato nel luglio 2023 sull’American Journal of Obstetrics and Gynecology, il tasso di incidenza della PCOS negli Stati Uniti è di 42,5 casi ogni 10.000 persone ogni anno. Inoltre, varie organizzazioni nel paese offrono valutazioni complete, creano consapevolezza e si concentrano sulla ricerca relativa alla PCOS. Ad esempio, il Centro UCSF per la salute riproduttiva è attivamente impegnato nella ricerca per studiare la causa della PCOS. Pertanto, l'elevata prevalenza della PCOS e la presenza di organizzazioni focalizzate sulla ricerca e sulla sensibilizzazione favoriscono la crescita del mercato del trattamento della sindrome dell'ovaio policistico (PCOS).

Industria Sviluppi e opportunità future:

Alcuni sviluppi strategici da parte dei principali attori che operano nel mercato del trattamento della sindrome dell'ovaio policistico (PCOS), secondo l'azienda comunicati stampa, sono elencati di seguito:

    •Nell'aprile 2023, Celmatix ha lanciato il programma farmacologico Novel PCOS. L'azienda ha presentato il suo programma terapeutico più recente, mirato ai recettori della melatonina all'esterno del sistema nervoso centrale (SNC). Il farmaco terapeutico colmerà una lacuna cruciale nel mercato per terapie di prima linea efficaci per varie condizioni di salute delle donne, a cominciare dalla PCOS e potenzialmente espandendosi fino a includere l'endometriosi e i sintomi della menopausa.•Nel gennaio 2022, Celmatix Inc. ha annunciato un risultato fondamentale nella sua alleanza multi-target quinquennale con Evotec. Evotec e Bayer AG hanno segnato un traguardo fondamentale per far avanzare un programma farmacologico contro la PCOS incentrato su un nuovo bersaglio farmacologico identificato da Celmatix nell'identificazione dei risultati.

Paesaggio competitivo e chiave Aziende:

Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc , AstraZeneca e Pfizer Inc sono tra le aziende di spicco descritte nel rapporto sul mercato del trattamento della sindrome dell'ovaio policistico (PCOS). Queste aziende si concentrano sullo sviluppo di nuove tecnologie, sull'aggiornamento dei prodotti esistenti e sull'espansione della propria presenza geografica per soddisfare la crescente domanda dei consumatori in tutto il mondo.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which distribution channel segment dominates the polycystic ovarian syndrome (PCOS) treatment market?

The market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest polycystic ovarian syndrome (PCOS) treatment market share in 2023, and it is anticipated to register the highest CAGR during the forecast period.

Which product segment dominates the polycystic ovarian syndrome (PCOS) treatment market?

By product, the market is segmented into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment held a larger polycystic ovarian syndrome (PCOS) treatment market share in 2023. Further, the clomiphene citrate segment is anticipated to register a faster CAGR during the forecast period.

What are the growth estimates for the polycystic ovarian syndrome (PCOS) treatment market till 2031?

The polycystic ovarian syndrome (PCOS) treatment market is expected to be valued at US$ 5.26 billion in 2031.

What was the estimated polycystic ovarian syndrome (PCOS) treatment market size in 2023?

The polycystic ovarian syndrome (PCOS) treatment market was valued at US$ 3.46 billion in 2023.

Who are the major players in the polycystic ovarian syndrome (PCOS) treatment market?

The polycystic ovarian syndrome (PCOS) treatment market majorly consists of the players, including Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc

What is polycystic ovarian syndrome (PCOS)?

Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that causes enlarged ovaries with cysts on their outer edges. Some symptoms of PCOS include excess hair growth, acne, missed or irregular menstrual periods, infertility, and weight gain.

What factors drive the polycystic ovarian syndrome (PCOS) treatment market?

Factors such as the increasing prevalence of polycystic ovary syndrome (PCOS) among women globally and increasing government initiatives and support for research in the field of reproductive health propel the polycystic ovarian syndrome (PCOS) treatment market growth. However, the limited availability of FDA-approved medications specifically for PCOS hamper the growth of the market.

The List of Companies - Polycystic Ovarian Syndrome (PCOS) Treatment Market

  1. Sanofi SA
  2. Merck KGaA
  3. Novartis
  4. Mylan
  5. Takeda Pharmaceutical Company Ltd
  6. Abbott
  7. Teva Pharmaceuticals
  8. Salix Pharmaceuticals, Inc
  9. AstraZeneca
  10. Pfizer Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports